相关实验视频
Updated: Jun 20, 2026
10:44
Two-photon Imaging of Cellular Dynamics in the Mouse Spinal Cord
Published on: February 22, 2015
10.3K
细胞外纯素代谢 - 多发性硬化症的潜在目标
Danijela Laketa1, Irena Lavrnja2
1Department of General Physiology and Biophysics, Institute for Physiology and Biochemistry "Ivan Djaja", Faculty of Biology, University of Belgrade, Studentski Trg 3, Belgrade, Republic of Serbia. danijela@bio.bg.ac.rs.
Molecular neurobiology
|March 19, 2024
概括
纯能系统对多发性硬化症 (MS) 病原发生有影响. 针对腺信号传递和P2Y12等特定受体,为MS中神经炎症提供了潜在的治疗策略.
科学领域:
- 神经免疫学 神经免疫学
- 分子生物学分子生物学
背景情况:
- 多发性硬化症 (MS) 是一种异质的神经炎症和神经退行性疾病.
- 纯能信号系统,涉及细胞外纯素和酶,在MS的发病过程中起着至关重要的作用.
- 在MS和其动物模型,实验性自身免疫脑膜炎 (EAE) 中,在免疫和中枢神经系统细胞中观察到纯能信号组件的改变.
研究的目的:
- 研究纯能信号系统在多发性硬化症 (MS) 和实验性自身免疫脑膜炎 (EAE) 中的作用.
- 在纯能系统内识别潜在的治疗点,以管理MS中神经炎症.
主要方法:
- 从MS患者和EAE模型中分析了外周免疫细胞和中枢神经系统 (CNS) 质细胞中的纯能信号组成部分.
- 评估细胞外核酸和核酸水平.
- 对核核酶活性的评估 (CD39/CD73).
- 研究腺受体 (A2A) 作用和遗传关联 (腺脱氨酶).
- 探索新的标,如P2Y12受体和NTPDase2.2,等.
主要成果:
- 细胞外ATP减少和腺/氨酸增加表明MS中向抗炎环境的转变.
- 在MS患者的血液和中枢神经系统中观察到的CD39/CD73ectonucleotidases的升调.
- 腺素信号通路显示出作为治疗点的前景,在EAE中具有益效的效果.
- 在MS中确定了依赖ADP的P2Y12受体和NTPDase2作为新的潜在标.
结论:
- 纯能信号系统在MS和EAE中发生显著变化,导致疾病的发病.
- 腺能系统,特别是腺受体,是神经炎症治疗的有希望的标.
- 包括P2Y12受体和NTPDase2在内的新目标需要进一步研究MS治疗方法.
相关概念视频
01:27Pharmacogenetics of Phase II Enzymes: N-acetyltransferase, Thiopurine S-methyltransferase, UDP-glucuronosyltransferase
Phase II biotransformation reactions are essential for detoxifying and eliminating xenobiotics, including many pharmaceutical compounds. These reactions typically involve conjugation, the covalent attachment of polar endogenous groups such as glucuronic acid, sulfate, methyl, or acetyl moieties to functional groups introduced during Phase I metabolism. The resulting conjugates are more water-soluble, enabling efficient renal or biliary excretion.The major classes of Phase II enzymes include...
01:11Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase
Genetic polymorphisms in drug targets have emerged as critical determinants of interindividual variability in drug response and toxicity. Pharmacogenomic investigations increasingly focus on identifying these variations to personalize and optimize therapeutic interventions. A drug target may be a receptor, enzyme, or signaling protein involved in pharmacologic responses or disease-related pathways. While early pharmacogenetic studies focused primarily on drug metabolism, current research...
01:29Pharmacogenomics: Identification of New Drug Targets
Advances in genomics have profoundly influenced drug discovery by increasing both the speed and accuracy of pharmaceutical development. Pharmacogenomics, which examines how genetic variation influences drug response, facilitates the identification of novel therapeutic targets and enables patient stratification for personalized treatment. These strategies contribute to improved drug efficacy, minimized adverse effects, and more efficient clinical trial design.Mapping genetic differences...
01:28Biosynthesis of Nucleic Acids
Nucleic acid biosynthesis is a fundamental biochemical process that produces the purine and pyrimidine nucleotides essential for DNA and RNA synthesis. This pathway maintains a balanced nucleotide pool, preventing imbalances that could jeopardize genetic integrity and cellular function. Given the crucial role of nucleotides, their synthesis is tightly regulated to ensure proper cellular homeostasis.Purine BiosynthesisThe biosynthesis of purine nucleotides begins with ribose-5-phosphate, a...
01:19Multiple Sclerosis l: Introduction
Multiple sclerosis is a chronic autoimmune disease of the central nervous system (CNS) that affects the brain, spinal cord, and optic nerves. It is an inflammatory demyelinating disorder and a leading cause of neurological disability in young adults.EpidemiologyMS commonly begins between 20 and 40 years of age and is twice as common in women. Its exact cause remains unclear, but genetic susceptibility contributes, with higher risk in first-degree relatives and identical twins. A greater...